CEO Sentenced to 3 Years for Selling Unapproved Stem Cell Treatments

John Kosolcharoen marketed stem cell products linked to hospitalizations, defrauding patients and misleading the FDA.

John Kosolcharoen, 53, pleaded guilty to introducing an unapproved drug into interstate commerce with intent to defraud.
Kosolcharoen's companies, Liveyon LLC and Genetech Inc., marketed injectable stem cell products made from umbilical cord blood.
The products were falsely advertised as treatments for serious conditions such as Alzheimer's, Parkinson's, and heart diseases.
Multiple patients were hospitalized due to bacterial infections linked to the unapproved stem cell treatments.
The FDA and CDC investigations revealed significant manufacturing and safety violations, leading to Kosolcharoen's conviction.